Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors

Nature Neuroscience

Volumn 10, Issue 7, 2007, Pages 870-879

  Agarwal, Nitin ^a   Pacher, Pal ^b   Tegeder, Irmgard ^c   Amaya, Fumimasa ^d   Constantin, Cristina E ^e   Brenner, Gary J ^d   Rubino, Tiziana ^f   Michalski, Christoph W ^a   Marsicano, Giovanni ^g   Monory, Krisztina ^g   Mackie, Ken ^h   Marian, Claudiu ^c   Batkai, Sandor ^b   Parolaro, Daniela ^f   Fischer, Michael J ⁱ   Reeh, Peter ⁱ   Kunos, George ^b   Kress, Michaela ^e   Lutz, Beat ^g   Woolf, Clifford J ^d   Kuner, Rohini ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DNA MODIFICATION; DRUG RECEPTOR BINDING; DRUG TARGETING; INFLAMMATION; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL;

ALLELES; ANALGESIA; ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; DNA PRIMERS; ELECTROPHYSIOLOGY; ENDOCANNABINOIDS; GANGLIA, SPINAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE FIBERS, UNMYELINATED; NEURONS, AFFERENT; NOCICEPTORS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTOR, CANNABINOID, CB1;

EID: 34347342722     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1916     Document Type: Article

References (46)

1. Walker, J.M. & Hohmann, A.G. Cannabinoid mechanisms of pain suppression. Handb. Exp. Pharmacol. 168, 509-554 (2005).
2. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389-462 (2006).
3. Freund, T.F., Katona, I. & Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017-1066 (2003).
4. Piomelli, D. The endocannabinoid system: a drug discovery perspective. Curr. Opin. Investig. Drugs 6, 672-679 (2005).
5. Patwardhan, A.M. et al. The cannabinoid WIN55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc. Natl. Acad. Sci. USA 103, 11393-11398 (2006).
6. + channels by membrane lipids. Science 304, 265-270 (2004).
7. Ledent, C. et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404 (1999).
8. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M. & Bonner, T.I. Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 5780-5785 (1999).
9. Ibrahim, M.M. et al. CB2 cannabinoid receptor mediation of antinociception. Pain 122, 36-42 (2006).
10. Kuhn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427-1429 (1995).
11. Marsicano, G. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88 (2003).
12. Agarwal, N., Offermanns, S. & Kuner, R. Conditional gene deletion in primary nociceptive neurons of trigeminal ganglia and dorsal root ganglia. Genesis 38, 122-129 (2004).
13. Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534 (2002).
14. Rubino, T., Vigano, D., Massi, P. & Parolaro, D. Changes in the cannabinoid receptor binding, G protein coupling and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J. Neurochem. 75, 2080-2086 (2000).
15. Ji, R.R., Baba, H., Brenner, G.J. & Woolf, C.J. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat. Neurosci. 2, 1114-1119 (1999).
16. Hartmann, B. et al. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. Neuron 44, 637-650 (2004).
17. Tsay, D.G. et al. Experimental acute pancreatitis. In vitro magnetic resonance characteristics. Invest. Radiol. 22, 556-561 (1987).
18. i in the ATP-induced heat sensitization process of rat nociceptive neurons. J. Neurophysiol. 81, 2612-2619 (1999).
19. Dogrul, A. et al. Topical cannabinoid antinociception: synergy with spinal sites. Pain 105, 11-16 (2003).
20. Pertwee, R.G. The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br. J. Pharmacol. 46, 753-763 (1972).
21. Richardson, J.D., Kilo, S. & Hargreaves, K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75, 111-119 (1998).
22. Pascual, D., Goicoechea, C., Suardiaz, M. & Martin, M.I. A cannabinoid agonist, WIN55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118, 23-34 (2005).
23. Fox, A. et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92, 91-100 (2001).
24. Valiveti, S., Hammell, D.C., Earles, D.C. & Stinchcomb, A.L. Transdermal delivery of the synthetic cannabinoid WIN55,212-2: in vitro/in vivo correlation. Pharm Res. 21, 1137-1145 (2004).
25. Bridges, D., Ahmad, K. & Rice, A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol. 133, 586-594 (2001).
26. Decosterd, I. & Woolf, C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149-158 (2000).
27. Hohmann, A.G. & Herkenham, M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90, 923-931 (1999).
28. Bridges, D. et al. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119, 803-812 (2003).
29. Binzen, U. et al. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience 142, 527-539 (2006).
30. Mitrirattanakul, S. et al. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126, 102-114 (2006).
31. Shire, D. et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270, 3726-3731 (1995).
32. 1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol. 448, 410-422 (2002).
33. Martin, W.J., Lai, N.K., Patrick, S.L., Tsou, K. & Walker, J.M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629, 300-304 (1993).
34. Azad, S.C. et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J. Neurosci. 24, 9953-9961 (2004).
35. Meng, I.D., Manning, B.H., Martin, W.J. & Fields, H.L. An analgesia circuit activated by cannabinoids. Nature 395, 381-383 (1998).
36. Finn, D.P. et al. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45, 594-604 (2003).
37. Martin, W.J., Loo, C.M. & Basbaum, A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 82, 199-205 (1999).
38. Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281 (1998).
39. Kolesnikov, Y.A., Jain, S., Wilson, R. & Pasternak, G.W. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J. Pharmacol. Exp. Ther. 279, 502-506 (1996).
40. Janson, W. & Stein, C. Peripheral opioid analgesia. Curr. Pharm. Biotechnol. 4, 270-274 (2003).
41. Sokal, D.M., Elmes, S.J., Kendall, D.A. & Chapman, V. Intraplantar injection of anandamide inhibits mechanically evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 45, 404-411 (2003).
42. Johanek, L.M. et al. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 93, 303-315 (2001).
43. Quartilho, A. et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99, 955-960 (2003).
44. Ulugol, A., Karadag, H.C., Ipci, Y., Tamer, M. & Dokmeci, I. The effect of WIN55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci. Lett. 371, 167-170 (2004).
45. Mackie, K. & Stella, N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 8, E298-E306 (2006).
46. Wang, L., Liu, J., Harvey-White, J., Zimmer, A. & Kunos, G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc. Natl. Acad. Sci. USA 100, 1393-1398 (2003).